We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Ms. Smith is the President and CEO of E-Scape Bio, Inc., a biotech company discovering and developing treatments for inherited neurodegenerative diseases. Prior to E-Sape Bio, Ms. Smith was President and Chief Executive Officer of Nuredis Inc., a biotech company developing treatments that target the cause of neurological and neuromuscular nucleotide repeat diseases. Previously she was Director, President and Chief Executive Officer of Raptor Pharmaceuticals until the company’s acquisition by Horizon Pharma plc. Prior to joining Raptor Ms. Smith served as Chief Commercial Officer of Enobia Pharmaceuticals until its acquisition by Alexion. Previously, Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals, Genzyme, Novazyme and Bristol-Myers Squibb. Ms. Smith currently serves as an Independent Director of Exelixis and Audentes. She previously served as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. She received her Bachelor of Science in biological and nutritional sciences from Cornell University.
This speaker's sessions: